Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections

J Exp Pharmacol. 2021 Jul 9:13:645-659. doi: 10.2147/JEP.S255211. eCollection 2021.

Abstract

Rhinovirus infection is common and usually causes mild, self-limiting upper respiratory tract symptoms. Rhinoviruses can cause exacerbation of chronic respiratory diseases, such as asthma or chronic obstructive pulmonary disease, leading to a significant burden of morbidity and mortality. There has been a great deal of progress in efforts to understand the immunological basis of rhinovirus infection. However, despite a number of in vitro and in vivo attempts, there have been no effective treatments developed. This review article summarises the up to date virological and immunological understanding of these infections. We discuss the challenges researchers face, and key solutions, in their work to investigate potential therapies including in vivo rhinovirus challenge studies. Finally, we explore past and present experimental therapeutic strategies employed in the treatment of rhinovirus infections and highlight promising areas of future work.

Keywords: antiviral agents; respiratory tract infections; rhinovirus; therapeutics.

Publication types

  • Review

Grants and funding

Sebastian Johnston is a National Institute of Health Research (NIHR) Emeritus Senior Investigator, the Asthma UK Clinical Chair (Grant CH11SJ) and receives support from European Research Council Advanced Grant 788575, the NIHR Imperial Biomedical Research Centre (BRC) and Asthma UK Centre Grant AUK-BC-2015-01. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.